Related Experiment Video

Updated: Aug 7, 2026

Interventional Diagnostic Procedure: A Practical Guide for the Assessment of Coronary Vascular Function
10:28

Interventional Diagnostic Procedure: A Practical Guide for the Assessment of Coronary Vascular Function

Published on: March 15, 2022

Economics methods in the Clinical Outcomes Utilizing percutaneous coronary Revascularization and Aggressive

William S Weintraub1, Paul Barnett, Shuo Chen

  • 1Atlanta VA Medical Center, Decatur, GA, USA. wweintraub@christianacare.org

American Heart Journal
|June 20, 2006
PubMed

Insights

Percutaneous coronary intervention (PCI) offers a major treatment for chronic coronary artery disease. This study evaluates the cost-effectiveness of PCI versus medical management alone, considering survival and quality-adjusted life years.

Area of Science:

  • Cardiology
  • Health Economics
  • Clinical Trials

Background:

  • Percutaneous coronary intervention (PCI) is a primary treatment for chronic coronary artery disease.
  • The COURAGE trial randomized 2287 patients to compare PCI with medical management versus medical management alone.

Purpose of the Study:

  • To conduct a detailed economic analysis of PCI versus medical management alone within the COURAGE trial.
  • To assess the cost-effectiveness of PCI across three diverse healthcare systems: US Veterans Administration, Canada, and US non-VA.
  • To determine the incremental cost-effectiveness ratio (ICER) of PCI based on survival and quality-adjusted life years (QALYs).

Main Methods:

  • Resource use and costs were collected across three healthcare systems.
  • Survival was assessed internally (4.5-year mean follow-up) and projected long-term.
  • Utility was measured using standard gamble to calculate QALYs.
  • Cost-effectiveness was analyzed using ICER, bootstrap analysis, cost-effectiveness plane, cost-effectiveness acceptability curves, and multilevel regression for net benefit.

Main Results:

  • Survival data was collected over a mean follow-up of 4.5 years.
  • Utility measures were obtained at multiple time points to calculate QALYs.
  • The study employed advanced statistical methods to determine the cost-effectiveness of PCI.

Conclusions:

  • The study provides a comprehensive assessment of PCI cost-effectiveness in chronic coronary artery disease.
  • Findings will inform clinical and policy decisions regarding PCI utilization.
  • The detailed economic analysis aims to offer the most thorough evaluation of PCI's value in managing coronary artery disease.

Related Concept Videos

Coronary Artery Disease V: Interprofessional Care01:27

Coronary Artery Disease V: Interprofessional Care

Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
Acute Coronary Syndrome IV: Interprofessional Care01:28

Acute Coronary Syndrome IV: Interprofessional Care

IntroductionThe management of Acute Coronary Syndrome (ACS) aims to minimize myocardial damage, preserve myocardial function, and prevent complications.Initial ManagementInpatient management involves continuous cardiac monitoring, preferably in an ICU, focusing on blood pressure, serum sodium, potassium, and creatinine levels, and urine output. Ongoing pharmacologic management is crucial for stabilizing the patient.Supplemental Oxygen: Administer supplemental oxygen if oxygen saturation is...
Angina IV: Management01:26

Angina IV: Management

IntroductionThe management of angina requires a comprehensive approach that includes pharmacological therapies, medical procedures, and lifestyle modifications.Pharmacological TherapiesAntiplatelet agents, such as aspirin, clopidogrel, prasugrel, and ticagrelor, play a pivotal role in preventing thrombus formation in patients with angina. These medications inhibit platelet aggregation and reduce the likelihood of myocardial infarction and other cardiovascular events.Anticoagulants, including...
Peripheral Artery Disease III: Interprofessional Care01:27

Peripheral Artery Disease III: Interprofessional Care

Peripheral Artery Disease (PAD) is characterized by narrowed arteries that diminish blood flow to the extremities. Effective management of PAD requires an interprofessional approach involving various healthcare professionals. The critical aspects of interprofessional care for PAD patients focus on risk factor modification, drug therapy, exercise therapy, nutrition therapy, critical limb ischemia care, and interventional radiology and surgical procedures.The primary treatment goal for PAD...
Clinical Trials01:16

Clinical Trials

Clinical trials are prospective experimental studies conducted on humans to determine the safety and efficacy of treatments, drugs, diet methods, and medical devices. Using statistics in clinical trials enables researchers to derive reasonable and accurate conclusions from the collected data, allowing them to make wise decisions in uncertain situations. In medical research, statistical methods are crucial for preventing errors and bias.
There are four phases in a clinical trial. A phase one...
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...